AcelRx Pharmaceuticals, Inc. Announces Executive Changes
June 02, 2014 at 04:13 pm
Share
AcelRx Pharmaceuticals, Inc. announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of Chief Executive Officer of a medical device company. Richard King, the Company's President and Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer, and will lead the continued build-out of the commercial organization and launch preparation for Zalviso until a suitable replacement is found. Mr. King has served as a director, president and chief executive officer for AcelRx since May 2010.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.